Trial Profile

A trial assessing PegiHep for patients with COVID-19

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Zydus Cadila

Most Recent Events

27 Jul 2020 New trial record
17 Jul 2020 According to Zydus Cadila media release, the company is also working with USFDA to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com